Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)
Key features and details
- Rabbit polyclonal to VEGF Receptor 2 (phospho Y951)
- Suitable for: ELISA, WB, IHC-P, ICC/IF
- Reacts with: Mouse, Human
- Isotype: IgG
Overview
-
Product name
Anti-VEGF Receptor 2 (phospho Y951) antibody
See all VEGF Receptor 2 primary antibodies -
Description
Rabbit polyclonal to VEGF Receptor 2 (phospho Y951) -
Host species
Rabbit -
Tested applications
Suitable for: ELISA, WB, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat
-
Immunogen
Synthetic peptide corresponding to Human VEGF Receptor 2 (phospho Y951).
-
Positive control
- WB: SK-OV3 cell extract. IHC-P: Breast carcinoma tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
The antibody was affinity purified from rabbit antiserum by affinity chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab38473 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ELISA |
Use at an assay dependent concentration.
|
|
| WB |
1/500 - 1/1000. Detects a band of approximately 190 kDa (predicted molecular weight: 151 kDa).
|
|
| IHC-P |
1/50 - 1/100.
|
|
| ICC/IF | (2) |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
ELISA
Use at an assay dependent concentration. |
|
WB
1/500 - 1/1000. Detects a band of approximately 190 kDa (predicted molecular weight: 151 kDa). |
|
IHC-P
1/50 - 1/100. |
|
ICC/IF
Use at an assay dependent concentration. |
Target
-
Function
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3791 Human
- Entrez Gene: 16542 Mouse
- Entrez Gene: 25589 Rat
- Omim: 191306 Human
- SwissProt: P35968 Human
- SwissProt: P35918 Mouse
- SwissProt: O08775 Rat
- Unigene: 479756 Human
see all -
Alternative names
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)ab38473 at a 1:50 dilution staining VEGF Receptor 2 in Human breast carcinoma tissue using Immunohistochemistry, Paraffin Embedded Tissue.
Left image : untreated.
Right image : treated with phosphopeptide.
-
Western blot - Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)All lanes : Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)
Lane 1 : SK-OV-3 (Human ovarian cancer cell line) cell lysate. Treated with phosphopeptide
Lane 2 : SK-OV-3 (Human ovarian cancer cell line) cell lysate
Predicted band size: 151 kDa
Observed band size: 230 kDa why is the actual band size different from the predicted?VEGFR2 is translated into a 150 kDa protein. Glycosylation of the extracellular domain results in the mature form at the cell surface which migrates at 230 kDa via western blot.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab38473 has been referenced in 8 publications.
- Desjarlais M et al. Tyrosine-Protein Phosphatase Non-receptor Type 9 (PTPN9) Negatively Regulates the Paracrine Vasoprotective Activity of Bone-Marrow Derived Pro-angiogenic Cells: Impact on Vascular Degeneration in Oxygen-Induced Retinopathy. Front Cell Dev Biol 9:679906 (2021). PubMed: 34124069
- Li C et al. HIF-1a/VEGF signaling-mediated epithelial-mesenchymal transition and angiogenesis is critically involved in anti-metastasis effect of luteolin in melanoma cells. Phytother Res 33:798-807 (2019). PubMed: 30653763
- Huang M et al. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell. BMC Gastroenterol 18:169 (2018). PubMed: 30400838
- Zhao G et al. The Soluble VEGF Receptor sFlt-1 Contributes to Impaired Neovascularization in Aged Mice. Aging Dis 8:287-300 (2017). PubMed: 28580185
- Kapur S et al. Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis. Bioeng Transl Med 2:81-91 (2017). WB . PubMed: 28516164
- Zhang W et al. Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation. Oncol Lett 14:5409-5417 (2017). PubMed: 29142602
- Koyama Y et al. Endothelin-1 increases the expression of VEGF-R1/Flt-1 receptors in rat cultured astrocytes through ETB receptors. J Neurochem 130:759-69 (2014). PubMed: 24862165
- Sangaletti S et al. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 68:9050-9 (2008). IHC-P ; Mouse . PubMed: 18974151